N/A N=33 Microneedle Patch Study in Healthy Infants/Young Children
Vaccination · Skin Absorption
Primary: Number of Participants With Placebo Microneedle Patch-related Serious Adverse Events (SAE). — 0; 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=261 Intravenous Magnesium Infusion in Patients Undergoing Cardioversion of Atrial Fibrillation Trial
Atrial Fibrillation
Primary: Number of Participants With Successful Cardioversion of Atrial Fibrillation to Sinus Rhythm — 114; 111 Participants
N/A N=4,819 A Study on the Control of Chronic Obstructive Pulmonary Disease (COPD) in Patients Taking the Combination of Tiotropium and Olodaterol Using the Respimat® Inhaler
Pulmonary Disease, Chronic Obstructive
Primary: Percentage of Patients With Therapeutic Success of Spiolto® Respimat® Treatment at Visit 2 — 81.38 Percentage of participants
Phase 2 N=22 Cardiac Surgery Neuroprotection Study in Elders
Post-operative Cognitive Decline · Post-operative Delirium
Primary: Change From Baseline Cognitive Function
N/A N=120 Home Sleep and Circadian Phase: Mediators of Diabetes Risk
Sleep Deprivation · Diabetes · Circadian Dysregulation
Primary: Oral Disposition Index — 11.5 None (Index) — p=.13
Phase 3 N=396 BAY63-2521:Long-term Extension Study in Patients With Pulmonary Arterial Hypertension
Hypertension, Pulmonary
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAE) — 229; 108; 56; 138 Participants
Phase 3 N=298 Dexamethasone vs Placebo in the Prophylaxis of Radiation-Induced Pain Flare Following Palliative Radiotherapy for Bone Metastases
Bone Metastases
Primary: Radiation-induced Pain Flare Incidence — 39; 53 Participants — p=0.05
Phase 3 N=326 Treatment of Patients With Nocturia (Non-PK Study)
Nocturia
Primary: Change in Mean Number of Nocturic Episodes/Night — -1.3; -1.2 nocturic episodes per night
Phase 3 N=4,994 Standard Issue Transfusion Versus Fresher Red Blood Cell Use in Intensive Care- A Randomised Controlled Trial
Transfusion · Age of Blood
Primary: Mortality at Day 90 — 610; 594; 264; 259 participants
N/A N=66 Evaluation of the Feasibility a New Silicone Hydrogel Contact Lens
Myopia
Primary: Visual Acuity — -0.038; -0.040 logMAR
Phase 1 N=37 Dose-finding Study of GSK2636771 When Administered in Combination With Enzalutamide in Male Subjects With Metastatic Castration-Resistant Prostate Cancer
Neoplasms
Primary: Number of Participants With Non-serious Adverse Events (Non-SAEs) and Serious Adverse Events (SAEs) During run-in Period — 11; 1 Participants
N/A N=20 Breathalyzer Validation Study
Alcohol Drinking · Alcohol Intoxication
Primary: Percentage Alcohol in Breath Variability — 0.0912; 0.0968; 0.0694; 0.0912 percentage of alcohol — p=<.0001
Phase 2 N=24 Effect of Banaba (Lagerstroemia Speciosa) on Metabolic Syndrome, Insulin Secretion and Insulin Sensitivity
Metabolic Syndrome X
Primary: Triglyceride Levels at Week 12 — 148.0; 199.9 mg/dL — p=0.021
N/A N=8 The Effect of Macronutrients on Satiety and Gut Hormone Responses
Eating Behavior
Primary: The Effect of Proteins on the Secretion of Gut Hormones From Different Parts of the Gastrointestinal Tract — 1310; 1073; 1118; 1188 pg*min/mL
Phase 3 N=194 The BASE Study: Bicarbonate Administration to Stabilize Estimated Glomerular Filtration Rate (eGFR)
Chronic Kidney Disease
Primary: Number of Participants in Each Dose Arm Prescribed (i) Full Randomized Sodium Bicarbonate Dose at End of 28 Weeks & (ii) at Least 25% of Randomized Sodium Bicarbonate…